Physician profile
Robert Savory
NPI 1619968229
$7,902.62
in general payments reported to CMS, 2019-2025
31 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,499 · 2020: $1,409 · 2021: $1,406 · 2022: $435 · 2023: $990 · 2024: $895 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,472.61 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $1,014.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $540.53 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $501.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $497.90 | 2019-2021 | |
| Abbvie INC. | $474.92 | 2020-2023 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.87 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $384.62 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $376.27 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $290.49 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $229.12 | 2019-2023 | Veozah |
| Avanir Pharmaceuticals, INC. | $225.83 | 2019 | |
| Allergan, INC. | $210.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $200.11 | 2019-2023 | |
| Glaxosmithkline, LLC. | $176.85 | 2019-2025 | Shingrix, Arexvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $176.08 | 2019-2020 | |
| Amarin Pharma, INC. | $142.44 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $107.10 | 2019-2021 | |
| Abbott Laboratories | $92.42 | 2021-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $91.21 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $75.40 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.43 | 2021 | |
| Eisai INC. | $34.07 | 2021 | |
| Dexcom, INC. | $21.72 | 2024 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $21.11 | 2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $19.34 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $18.75 | 2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $18.64 | 2019 | |
| Athena Bioscience, LLC | $14.86 | 2023 | Nexiclon Xr |
| Esperion Therapeutics, INC. | $13.88 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Savory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.